Live Breaking News & Updates on Lifespan Educational Advisory Committee

Stay updated with breaking news from Lifespan educational advisory committee. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Dr Sikov on the Use of CDK4/6 Inhibitors in the First-line Treatment of ER+/HER2- Breast Cancer

William M. Sikov, MD, discusses the negative outcome seen with palbociclib in the phase 3 PALOMA-2 trial, and compares this to data on other CDK4/6 inhibitors in the first-line treatment of estrogen receptor–positive, HER2-negative breast cancers. ....

Rhode Island , United States , Williamm Sikov , Lifespan Educational Advisory Committee , Lifespan Cancer Institute , Infants Hospital , Onclive Tv , Breast Cancer , Cdk4 6 Inhibitors , Her2 Negative Breast Cancers , Hr Positive Breast Cancer ,

Dr Sikov on the Benefit of CDK4/6 Inhibitors in HR+/HER2-Negative Breast Cancer

William M. Sikov, MD, discusses the benefit of CDK4/6 inhibitors in the treatment of hormone receptor–positive/HER2-negative breast cancers. ....

Rhode Island , United States , Williamm Sikov , Lifespan Cancer Institute , Lifespan Educational Advisory Committee , Infants Hospital , Onclive Tv , Breast Cancer , Cdk4 6 Inhibitors , Her2 Negative Breast Cancers , Hr Positive Breast Cancer ,